Hanbury FZE
  • Search
  • Home
  • Products & Services
    • Nutraceutical Ingredients
      • Standardized Phyto Extracts
      • Beverage/Liquid Dietary Supplements
      • GRAS Affirmed Ingredients
      • Minerals for Nutritional Use
      • Phytochemicals for Nutritional Use
      • Multi-enzyme Blends
      • Natural Protein
      • Nutritional Fine Chemicals
      • Phyto Functional Blends
      • Geroceuticals™
      • Prebiotics, Probiotics, Postbiotics and Synbiotics
      • Super Critical Fluid (SCF) Extracts
      • Specialty Fine Chemicals
    • Cosmeceutical Ingredients
      • Natural Actives
      • Peptides
      • Anti-Glycation
      • Dermaceuticals
      • Nutricosmetics
      • Probiotics & Postbiotics
      • Proprietary Cosmeceutical Blends
      • Speciality Chemicals
    • Services
      • Custom Manufacturing
      • Contract Manufacturing
      • Product Specification Sheet
    • Pharma
      • Natural Drugs
      • Chiral Drug Intermediates
  • About Us
    • Our Story
    • Our People
    • Research & Development
    • Manufacturing Facilities
    • Intellectual Properties
  • Newsroom
    • Press Release
    • FAQs
      • BioPerine®
      • Citrin®K
      • Cococin™
      • Curcumin C3 Complex®
      • Curcumin C3 Reduct®
      • ForsLean®
      • GarCitrin®
      • LactoSpore®
      • LeanGard®
  • Contact Us

Home / Sabinsa’s Curcumin C3 Complex® and Aspirin Combination Researched in Groundbreaking Colorectal Cancer Study

Sabinsa’s Curcumin C3 Complex® and Aspirin Combination Researched in Groundbreaking Colorectal Cancer Study

Sabinsa’s Curcumin C3 Complex® and Aspirin Combination Researched in Groundbreaking Colorectal Cancer Study

In an extensive efficacy and mechanistic study using transcriptomic analysis using RNA-seq published in the leading journal Biochemical Pharmacology (Volume 135, 1 July 2017, Pages 22-34), researchers provided the first evidence of chemopreventive effect of a low dose combination of aspirin and Sabinsa’s Curcumin C3 Complex®.

Colorectal cancer (CRC) is one of the major causes of human mortality and morbidity. Colitis-accelerated colon cancer (CAC) is a sub-type of CRC that is also closely associated with inflammatory bowel disease (IBD). Although aspirin has been widely investigated as a chemopreventive agent for CAC and different types of CRC, the potential side-effect of gastrointestinal bleeding has been a concern in long-term high-dose aspirin therapy.  In this new study on animals, researchers at Rutgers discovered that co-administration of Curcumin C3 Complex® and aspirin helps to lower the dose of aspirin by 50% rendering this therapy feasible without adverse effects. It has been known earlier that Curcumin C3 complex® is non-toxic at all tested doses.

Additionally aspirin and C3 Complex combination modulated a larger gene sets than the single agent treatment. These genes were involved in several canonical pathways important in the inflammatory network and liver metastasis in CAC. Also this was the first study is first of its kind in an Azoxymethane(AOM)/DSS (Dextran sulfate sodium)-induced CAC.

“Extensive research on Curcumin C3 Complex continues to reveal additional applications and benefits, which fosters further studies added to the large body of science on C3 Complex,” said Sabinsa founder Dr. Muhammed Majeed. “The range of health benefits scientific investigation has identified continues to inspire researchers across the globe.”

The study, Mechanisms of colitis-accelerated colon carcinogenesis and its prevention with the combination of aspirin and curcumin: Transcriptomic analysis using RNA-seq, can be accessed here http://dx.doi.org/10.1016/j.bcp.2017.02.021

Back
top

HEADQUARTERS

Hanbury FZE


Jebel Ali Free Zone


Warehouse No. RA08AB05


P O Box. 61091


Dubai


United Arab Emirates


+971 4 883 8981

+971 4 883 8978

mail@hanburyfze.ae

CERTIFICATES

Certificate Logos Certificate Logos Certificate LogosCertificate Logos

Global Contacts List

USA India
Utah, USA Japan
Australia Poland
Brasil Korea
Canada South Africa
China Vietnam
Germany  

CONTACT US

    © 2023 Hanbury FZE. All Rights Reserved | Powered by Edkal Technologies | Privacy Policy | Terms of Use | Sitemap | Disclaimer

    • Facebook
    • Twitter
    • LinkedIn
    Disclaimer

    US-FDA: This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Usage disclaimer: The information pertaining to any marketing materials by Sabinsa, is for general purposes only. Users are urged to check the validity of patents if any, on any Sabinsa items for their intended use.

    EFSA: This statement has not been evaluated by the EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.

    Australia: Please note as an ingredient supplier the information contained in this website is for marketers of finished products formulations and is not intended as consumer advice. Marketers should ensure finished products are lawful and comply with the regulations of the countries in which these items are sold. Every care has been taken to ensure the accuracy of the information provided at the time of publication.